(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of 666.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.49%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.73%.
Nrx Pharmaceuticals's revenue in 2026 is $2,293,000.On average, 6 Wall Street analysts forecast NRXP's revenue for 2026 to be $3,930,121,052, with the lowest NRXP revenue forecast at $887,610,304, and the highest NRXP revenue forecast at $9,182,962,602. On average, 5 Wall Street analysts forecast NRXP's revenue for 2027 to be $14,793,022,013, with the lowest NRXP revenue forecast at $4,438,051,520, and the highest NRXP revenue forecast at $21,095,055,172.
In 2028, NRXP is forecast to generate $40,467,784,064 in revenue, with the lowest revenue forecast at $37,170,945,792 and the highest revenue forecast at $43,511,019,392.